Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research

flaxseed and Reduced Diastolic Blood Pressure

Research synthesisModerate evidenceMixed effect size4 studies · 3 beneficial · 1 neutral · 0 harmful

Across 4 studies (3 beneficial, 1 neutral), flaxseed supplementation shows moderate evidence for a small-to-moderate reduction in diastolic blood pressure, primarily in clinical populations with type 2 diabetes, metabolic diseases, or hypertension. Three of four studies reported statistically significant reductions, with effect sizes ranging from small to moderate (e.g., weighted mean differences of -2.50 to -4.87 mmHg). No consistent dose or form was reported across studies.

  • Studied populations: clinical populations with type 2 diabetes, metabolic diseases, cardiovascular risk factors, or hypertension

Caveats: Available evidence is overwhelmingly positive — 3 of 4 studies are beneficial and statistically significant — but publication bias is a concern (null-result studies are less likely to be published or indexed). The evidence base is also small (only 4 studies), so conclusions should be considered preliminary. Dose and form data were not consistently reported, limiting practical guidance. The neutral finding from the highest-quality study (evidence score 7, meta-analysis in type 2 diabetes) did not reach statistical significance (p = 0.060), suggesting the effect may be less robust in certain populations or when higher-quality evidence is considered.

Generated Jun 10, 2026
Doses used in studies
  • Glycinate · mg/day: 420 (median 420, IQR 420420) 1 study
4 of 4 papers
Back to top